ALK and non-small cell lung carcinoma: Patients with ALK-positive NSCLC are more likely to develop brain metastases compared to those with RET or ROS1 rearrangements.[13] Lorlatinib significantly improves PFS in patients with or without baseline brain metastases, and more than half of central nervous system adverse events (AEs) resolve spontaneously without intervention or dose adjustment.[12] These findings indicate that lorlatinib has a clear advantage over other ALK inhibitors in delaying or preventing brain metastases.